Jpmorgan Chase & CO Alx Oncology Holdings Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALXO
# of Institutions
120Shares Held
41.2MCall Options Held
518KPut Options Held
142K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$14.5 Million33.06% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.22MShares$6.29 Million3.76% of portfolio
-
Redmile Group, LLC San Francisco, CA4.04MShares$6.01 Million1.59% of portfolio
-
Vestal Point Capital, LP New York, NY3.6MShares$5.36 Million1.62% of portfolio
-
Black Rock Inc. New York, NY2.69MShares$4 Million0.0% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $60.7M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...